Copyright
©The Author(s) 2022.
World J Diabetes. Feb 15, 2022; 13(2): 85-96
Published online Feb 15, 2022. doi: 10.4239/wjd.v13.i2.85
Published online Feb 15, 2022. doi: 10.4239/wjd.v13.i2.85
Table 3 Modification of dosing for dipeptidyl peptidase 4 inhibitors in hepatic impairment
| Hepatic impairment | Alogliptin | Linagliptin | Sitagliptin | Vildagliptin | Saxagliptin |
| Mild | 25 mg o.d. | 5 mg o.d. | 100 mg o.d. | Not recommended in liver disease, including AST or ALT > 3 × ULN | 5 mg o.d. |
| Moderate | 25 mg o.d. | 5mg o.d. | 100 mg o.d. | Can be used with caution | |
| Severe | Not recommended | 5 mg o.d. | Can be used with caution | Not recommended |
- Citation: Florentin M, Kostapanos MS, Papazafiropoulou AK. Role of dipeptidyl peptidase 4 inhibitors in the new era of antidiabetic treatment. World J Diabetes 2022; 13(2): 85-96
- URL: https://www.wjgnet.com/1948-9358/full/v13/i2/85.htm
- DOI: https://dx.doi.org/10.4239/wjd.v13.i2.85